Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
The Journal of Urology|July 13, 2022
Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical ProstatectomyElio Mazzone, Giorgio Gandaglia, Armando Stabile, et al.
Clinical Genitourinary Cancer|November 8, 2017
Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical ResearchAndrea Necchi, Salvatore Lo Vullo, Patrizia Giannatempo, et al.
European Urology Oncology|September 20, 2021
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference StandardArmando Stabile, Antony Pellegrino, Elio Mazzone, et al.
Clinical Genitourinary Cancer|July 17, 2014
Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial designAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
American Journal of Clinical Oncology|August 5, 2014
Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell TumorsDaniele Raggi, Patrizia Giannatempo, Rosalba Miceli, et al.
European Journal of Internal Medicine|July 12, 2022
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitorsCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
The Journal of Urology|November 23, 2013
The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experienceGiovanni Lughezzani, Mario Catanzaro, Tullio Torelli, et al.
Clinical Genitourinary Cancer|October 29, 2013
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomesAndrea Necchi, Nicola Nicolai, Luigi Mariani, et al.
The Journal of Urology|April 30, 2013
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatmentPatrizia Giannatempo, Biagio Paolini, Rosalba Miceli, et al.
Clinical Genitourinary Cancer|September 6, 2015
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant SettingsNicola Nicolai, Laura Maria Sangalli, Andrea Necchi, et al.
Pageof 13